Quadrant Capital Group LLC Verve Therapeutics, Inc. Transaction History
Quadrant Capital Group LLC
- $1.43 Billion
- Q4 2024
A detailed history of Quadrant Capital Group LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 2,518 shares of VERV stock, worth $18,331. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,518
Previous 1,202
109.48%
Holding current value
$18,331
Previous $5,000
180.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding VERV
# of Institutions
180Shares Held
76.4MCall Options Held
70.3KPut Options Held
194K-
Alphabet Inc. Mountain View, CA12.3MShares$89.9 Million4.92% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$50.3 Million1.46% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$48.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$29.2 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$29.1 Million1.94% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $436M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...